It sets a standard for future treatments, and it will probably be used with other drugs (e.g., with a GLP‐1 RA for an obese MASH patient to help with both weight and liver, or with an SGLT2 inhibitor for a diabetic MASH patient to help with blood sugar and liver control). The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatohepatitis.